Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Hemostemix Inc V.HEM

Alternate Symbol(s):  HMTXF

Hemostemix Inc. is a Canada-based autologous stem cell therapy company. The Company has developed, patented, and is scaling a patient’s blood-based stem cell therapeutics platform, which includes angiogenic cell precursors, neuronal cell precursors and cardiomyocyte cell precursors. The Company holds 87 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01, its lead clinical-stage candidate, is an autologous cell therapy for the treatment of critical limb ischemia. ACP-01 is in a Phase 2 clinical trial in Canada and the United States. Its technology includes methods for collecting the synergetic cell population and manufacturing a personalized regenerative therapy that can be administered to a patient within seven days of the initial cell collection. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd. and PreCerv Inc.


TSXV:HEM - Post by User

Bullboard Posts
Comment by duskwon Nov 17, 2009 12:37pm
158 Views
Post# 16495505

RE: Another 52 week low

RE: Another 52 week lowThe company has to stop bleeding money. Q1/Q2 gains, Q3/Q4 losses. The formula is simple - cut costs, increase revenue. Revenue seems to be elusive. It seems that the company is spending a lot in R&D. I hope that this will result in better products moving forward. Some of the product development times can be 2-3 years. Hopefully some of that prior investment will begin to pay-off soon with higher revenus in 2010.

It looks like 2009 will be a repeat of 2007. 2010 is going to be tough but I think it show growth and profit, assuming that the new products have some traction and overseas sales get some uptick. 2011 is too far so any real visibility. The 2010 proft will hopefully exceed 2008 losses and start to increase our cash position again.

Bullboard Posts